Change in Directors or Principal Officers

ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS

Cherry Hill, NJ, November 6, 2009, Nuvilex, Inc. (OTC Bulletin Board: NVLX), announced today that it has received amd accepted the resignation of Robert J. Creeden as a member of the Registrant's Board of Directors. Mr. Creeden has submitted his resignation due to policies set by Partners Innovation Fund and its parent, Partners Healthcare regarding the holding of board seats for publicly traded companies. Mr Creeden served as a member of the board of directors of Freedom2 and agreed to join the registrant's board to provide some continuity during the transition period.

About Nuvilex, Inc.

Nuvilex, Inc. is an emerging healthcare consumer products company. The Company’s lead products include: Last Shot Hangover Remedy™, a unique sugar-free, calorie-free and caffeine-free liquid formula designed to ease the symptoms of a hangover; Cinnergen™, which promotes a healthy glucose metabolism; Cinnechol™, designed to help maintain normal cholesterol levels and support normal cardiovascular function; and Infinitink®, a permanent yet more easily removable tattoo ink. The Company’s complete portfolio spans aesthetics, dermatology, environmental and nutraceutical products, all of which are designed to directly or indirectly improve human health. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., the developer of Infinitink ®. In conjunction with the merger, the Company changed its name to Nuvilex, Inc. from eFoodSafety.com. Please visit www.nuvilex.com for additional information on the Company.

Safe Harbor Statement

Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

Investor Relations Contacts:

Blair Barnes
Senior Vice President and Chief Financial Officer
Nuvilex, Inc.
Ph: 856-433-6088
Email: bbarnes@nuvilex.com

Press Contact:

Pat Arcand
Arcand & Madison
Ph: 617-576-7777
Email: pat@am-pr.com